黄芪多糖对铜绿假单胞菌致大鼠肺部感染的作用分析

doi:10.3877/cma.j.issn.1674-6902.2022.03.007

目的

分析黄芪多糖(astragalus polysaccharide, APS)对铜绿假单胞菌所致大鼠肺部感染的保护作用。

方法

经气管内注射铜绿假单胞菌制备肺部感染模型，将40只SD雄性大鼠随机分为对照组(Control)、模型组(Model)及APS治疗组(模型+100 mg/kg APS(Model+APS100)及模型+200 mg/kg APS(Model+APS200)组)。造模后24 h处死大鼠，测定肺组织湿干重比(W/D)，分别计数及ELISA测定支气管肺泡灌洗液的总炎症细胞数及TNF-α、IL-1β水平，使用Western blot法检测肺组织中NF-κB p65及IκBα蛋白磷酸化水平。

结果

与Control组相比，铜绿假单胞菌显著诱导肺组织W/D增加(P<0.05)，增加炎症细胞数(P<0.05)，使TNF-α、IL-1β表达(P<0.05)，并可诱导NF-κB p65/ IκBα发生磷酸化(P<0.05)，而给予APS治疗可明显逆转上述变化(P<0.05)，且高剂量组作用明显强于低剂量组(P<0.05)。

结论

APS可能通过抑制p65/ IκBα活性，减少TNF-α及IL-1β的产生，从而减轻铜绿假单胞菌引起的肺部感染。

关键词: 黄芪多糖, 铜绿假单胞菌, 肺部感染

Objective

To investigate the protective effects of astragalus polysaccharide (APS) on Pseudomonas aeruginosa induced pulmonary infection in rats.

Methods

Forty male SD rats were randomly divided into Control group, Model group and APS treatment group (Model+ 100 mg/kg APS (Model+ APS100) and Model+ 200 mg/kg APS (Model+ APS200). The rats were killed 24 hours after the model established. The wet/dry weight ratio (W/D ratio) of the lung tissue was measured. The number of total inflammatory cells and the levels of TNF-α and IL-1β in the bronchoalveolar lavage fluid were counted and measured by ELISA, respectively. The phosphorylation levels of p65 and IκBα protein in the lung tissue was measured by Western blot.

Results

Compared with Control group, Pseudomonas aeruginosa significantly increased the W/D ratio of lung tissues (P<0.05), the number of inflammatory cells (P<0.05), the expression of TNF-α and IL-1 β (all P<0.05), and the phosphorylation of NF-κB p65/IκBα (all P<0.05). While APS treatment could significantly reverse the above changes (all P<0.05), and the effects of high dose APS was significantly stronger than that of low dose APS (all P<0.05).

Conclusion

It is effective for APS in treatment of lung infectious disease induced by Pseudomonas aeruginosa by inhibiting the activity of NF-κB p65/IκBα and reducing the production of TNF-α and IL-1β.

Key words: Astragalus polysaccharide, Pulmonary infection, Pseudomonas aeruginosa

图1 APS对铜绿假单胞菌肺炎肺W/D比值的影响。与Control组相比，**P<0.01，***P<0.001；与Model组相比，&&P<0.01，&&&P<0.001；与Model+APS100组相比，#P<0.05

图2 APS对铜绿假单胞菌肺炎BALF中TNF-α和IL-1β水平的影响(图A、B)。与Control组相比，a：P<0.05；与Model组相比，b：P<0.05；与Model+APS100组相比，c：P<0.05

图3 APS对铜绿假单胞菌肺炎BALF中炎症细胞数的影响；注：A：总炎症细胞数，B：巨噬细胞数，C：淋巴细胞数，D：中性粒细胞数。与Control组相比，*P<0.05，**P<0.01；与Model组相比，&P<0.05，&&P<0.01；与Model+APS100组相比，#P<0.05

图4 APS抑制铜绿假单胞菌诱导肺部感染的NF-κB p65/IκBα通路活化；注：与Control组相比，a：P<0.05；与Model组相比，b：P<0.05；与Model+APS100组相比，c：P<0.05

1	Imran M, Amjad A, Haidri FR. Frequency of hospital acquired pneumonia and its microbiological etiology in medical intensive care unit[J]. Pak J Med Sci, 2016, 32(4): 823-826.
2	Agrafiotis M, Siempos II, Ntaidou TK, et al. Attributable mortality of ventilator-associated pneumonia: a meta-analysis[J]. Int J Tuberc Lung Dis, 2011, 15(9): 1154-1163, i-v.
3	Kollef MH, Hamilton CW, Ernst FR. Economic impact of ventilator-associated pneumonia in a large matched cohort[J]. Infect Control Hosp Epidemiol, 2012, 33(3): 250-256.
4	张玉江，张　巧，任之栋，等. PSI、APACHEⅡ和SOFA三种评分对医院获得性肺炎预后的评估价值[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(3): 285-288
5	许　静，陈　炜，张　鸿，等. 医院获得性肺炎的治疗及预防进展[J/CD]. 中华肺部疾病杂志(电子版), 2022, 15(1): 123-126.
6	Tsay TB, Jiang YZ, Hsu CM, et al. Pseudomonas aeruginosa colonization enhances ventilator-associated pneumonia-induced lung injury[J]. Respir Res, 2016, 17(1): 101.
7	Ramphal R, Balloy V, Jyot J, et al. Control of Pseudomonas aeruginosa in the lung requires the recognition of either lipopolysaccharide or flagellin[J]. J Immunol, 2008, 181(1): 586-592.
8	El Solh AA, Alhajhusain A. Update on the treatment of pseudomonas aeruginosa pneumonia[J]. J Antimicrob Chemother, 2009, 64(2): 229-238.
9	Jacqueline C, Roquilly A, Desessard C, et al. Efficacy of ceftolozane in a murine model of Pseudomonas aeruginosa acute pneumonia: in vivo antimicrobial activity and impact on host inflammatory response[J]. J Antimicrob Chemother, 2013, 68(1): 177-183.
10	Driscoll JA, Brody SL, Kollef MH. The epidemiology, pathogenesis and treatment of pseudomonas aeruginosa infections[J]. Drugs, 2007, 67(3): 351-368.
11	Li J, Zou M, Dou Q, et al. Characterization of clinical extensively drug-resistant Pseudomonas aeruginosa in the Hunan province of China[J]. Ann Clin Microbiol Antimicrob, 2016, 15(1): 35.
12	Ren Q, Zhao S, Ren C, et al. Astragalus polysaccharide alleviates LPS-induced inflammation injury by regulating miR-127 in H9c2 cardiomyoblasts[J]. Int J Immunopathol Pharmacol, 2018, 32: 2058738418759180.
13	Lu J, Chen X, Zhang Y, et al. Astragalus polysaccharide induces anti-inflammatory effects dependent on AMPK activity in palmitate-treated RAW264.7 cells[J]. Int J Mol Med, 2013, 31(6): 1463-1470.
14	Wang X, Li Y, Yang X, et al. Astragalus polysaccharide reduces inflammatory response by decreasing permeability of LPS-infected Caco2 cells[J]. Int J Biol Macromol, 2013, 61: 347-352.
15	Wang XH, Huang WM. Astragalus polysaccharides exert protective effects in newborn rats with bronchopulmonary dysplasia by upregulating the expression of EGFL7 in lung tissue[J]. Int J Mol Med, 2014, 34(6): 1529-1536.
16	Liu QY, Yao YM, Zhang SW, et al. Astragalus polysaccharides regulate T cell-mediated immunity via CD11c(high)CD45RB(low) DCs in vitro[J]. J Ethnopharmacol, 2011, 136(3): 457-464.
17	Yuan LB, Hua CY, Gao S, et al. Astragalus polysaccharides attenuate monocrotaline-induced pulmonary arterial hypertension in rats[J]. Am J Chin Med, 2017, 45(4): 773-789.
18	Cai S, Li Y, Wang K, et al. Pathogenic Effects of biofilm on pseudomonas aeruginosa pulmonary infection and its relationship to cytokines[J]. Med Sci Monit, 2016, 22: 4869-4874.
19	Wang Q, Ma L, Liu T, et al. TIPE2 suppresses pseudomonas aeruginosa keratitis by inhibiting NF-κB signaling and the infiltration of inflammatory cells[J]. J Infect Dis, 2019, 220(6): 1008-1018.
20	Tak PP, Firestein GS. NF-kappa B: a key role in inflammatory diseases[J]. J Clin Invest, 2001, 107(1): 7-11.

[1]	陈经欣, 李梅, 陈洁雅. 肺结节胸腔镜术后肺部感染危险因素分析[J]. 中华实验和临床感染病杂志(电子版), 2023, 17(04): 238-243.
[2]	林亚丽, 朱丹, 李云霞, 刘晓芳. 慢性呼吸衰竭合并肺部念珠菌感染的临床特征及影响因素[J]. 中华实验和临床感染病杂志(电子版), 2022, 16(06): 385-390.
[3]	张长文, 林少清, 吕敏捷, 金霄, 朱常军, 冯旰珠. 铜绿假单胞菌分泌蛋白Pec1抑制巨噬细胞自噬及影响铜绿假单胞菌清除效应初步观察[J]. 中华实验和临床感染病杂志(电子版), 2022, 16(06): 370-376.
[4]	周杉京, 诸葛金科, 王芳芳. 补肺活血胶囊对COPD患者cCor、ALD、Ang-Ⅱ的影响[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 517-519.
[5]	王庆, 张红联, 吴志勇. COPD合并多重耐药菌肺部感染预后危险因素分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 557-559.
[6]	刘玲, 肖颖, 王蓉. 严重创伤并发肺部感染死亡病例分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 581-583.
[7]	张晓娟, 邓祥瑞, 陈睿, 钟文. AECOPD伴肺部感染吸入三联疗效与EOS相关性分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(03): 364-366.
[8]	梁华, 黄承军, 鄂桂香, 李静. 胸腺肽多索茶碱治疗COPD并发肺部感染的临床分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(02): 218-220.
[9]	张沥, 宋俊华, 何皓, 杨雪瑶, 周康. 血清D-D、PAI-1、sICAM-1水平与糖尿病合并肺部感染病情严重程度及预后的关系[J]. 中华肺部疾病杂志(电子版), 2023, 16(02): 203-205.
[10]	叶晓芳, 杨京华, 武元星, 朱光发. COPD患者冠状动脉旁路移植术后肺部感染的预后影响及危险因素分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(02): 175-179.
[11]	崔立慧, 李士荣, 李素娟, 孙娴静, 张馨怡. 糖尿病患者肺部感染超敏C反应蛋白和降钙素原检测的临床意义[J]. 中华肺部疾病杂志(电子版), 2023, 16(01): 95-97.
[12]	汪玲玲, 申潇竹, 贾嵘, 包勤文. CRP/AIb、NLR及CD64%对老年肺部感染预后的意义[J]. 中华肺部疾病杂志(电子版), 2022, 15(06): 859-862.
[13]	孙骥, 刘牧野, 戈国亮, 彭薇, 戴梅. NLR、IL-6及C反应蛋白水平对涂阳肺结核患者继发肺部感染的预测意义[J]. 中华肺部疾病杂志(电子版), 2022, 15(05): 694-696.
[14]	张焱, 杨莉莉, 杨景森, 季迪, 宋彩萍. 慢性鼻窦炎FESS术后并发肺部感染危险因素分析[J]. 中华肺部疾病杂志(电子版), 2022, 15(05): 653-656.
[15]	李欢, 唐钰书, 王璇, 谢席胜. 慢性肾脏病患者肺部感染的诊治进展[J]. 中华肾病研究电子杂志, 2022, 11(05): 285-289.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Effect of astragalus polysaccharide on pulmonary infection induced by Pseudomonas aeruginosa in rats

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Effect of astragalus polysaccharide on pulmonary infection induced by Pseudomonas aeruginosa in rats